They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Leading pharmaceutical companies, including Dr Reddy's, Sun Pharma, Cipla, Mankind Pharma, and Natco Pharma, among others, ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Colonel Jeffrey D. Glover and Dr. Benjamin F. Chavis Jr. The new FDA-approved weight loss medicines have changed the game for people with obesity, offering millions of Americans a chance to transform ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...